Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on harnessing the potential of hypoxia-inducible factor (HIF)
biology to develop and commercialize novel therapeutics to treat kidney
disease, today announced that Michael D.
for Akebia Therapeutics Appoints Michael Clayman, M.D. and Maxine Gowen, Ph.D. to its Board of Directors investment picks